Skip to main content
. 2021 Sep 7;5:PO.20.00439. doi: 10.1200/PO.20.00439

TABLE 3.

Cancer Sites, Mutational Status, and Extent and Duration of Response of Patients Who Received Olaparib and Ceralasertib/AZD6738

graphic file with name po-5-po.20.00439-g003.jpg